SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Symbiotec Pharmalab Ltd Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

BSE: 0 NSE: | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

Symbiotec Pharmalab Ltd

BSE: 0 NSE:
Key Metrics
Market Cap
₹0 Cr.
P/E Ratio
0.00
Price to Book (P/B)
0.00
Price to Sales (P/S)
0.00
EV/EBITDA
0.00
Return on Capital Employed (ROCE)
15.75%
Current Price
₹0
Return on Equity (ROE)
12.41%
Return on Assets (ROA)
8.88%
Operating Profit Margin
21.3%
Net Profit Margin
13.2%
Gross Profit Margin
23%
Book Value per Share
₹0
Sales Growth (YoY)
19.52%
Sales Growth (3 Years)
2.65%
Operating Profit Growth (1 Year)
78.47%
Operating Profit Growth (3 Years)
-10.94%
Net Profit Growth (1 Year)
NA%
52-Week Low / High
₹0 / 0
Net Profit Growth (3 Years)
-13.11%
Dividend Yield
0.00%
Promoter Holding
%
Pledged shares (%)
of Promoter's holding (%)
%

DeciZen - make an informed investing decision on Symbiotec Pharmalab

Based on:

DeciZen not available for IPO

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 16.2%13.4%14.7%15.1%14.5%16.9%29.1%11.9%0%15.8%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 389419438410528531623634564674528
Sales YoY Gr.-7.6%4.6%-6.4%28.9%0.7%17.3%1.8%-11.1%19.5%-
Adj EPS 65.38.57.98.913.324.511.34.415.60
YoY Gr.--11.6%60.7%-6.2%12.6%48.8%84.4%-54%-61.4%258.3%-
BVPS (₹) 455061.168.977.891115.8127.1123.1139.20
Adj Net
Profit
32.328.645.943.148.872.713461.723.985.4NAN
Cash Flow from Ops. 28.519.252.348.343.710915823.593.4147-
Debt/CF from Ops. 6.510.33.33.23.51.10.32.71.20.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 6.3%5%2.7%19.5%
Adj EPS 11.3%11.8%-13.9%258.3%
BVPS13.4%12.4%6.3%13.1%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
14.111.115.212.212.215.723.79.33.511.90
Op. Profit
Mgn %
1717.719.422.518.922.532.516.614.721.3NAN
Net Profit
Mgn %
8.36.810.510.59.313.721.59.74.212.7NAN
Debt to
Equity
0.80.70.50.40.40.20.10.10.20.1-
Working Cap
Days
1631982162462312602212463163260
Cash Conv.
Cycle
56841001351271361011371791120

Recent Performance Summary

Recent Performance Summary not available for IPO

Recent Performance Summary not available for IPO

Latest Financials

Standalone Consolidated
TTM EPS (₹) 0 -
TTM Sales (₹ Cr.) 528 -
BVPS (₹) 0 -
Reserves (₹ Cr.) 414 -
P/BV 0.00 -
PE 0.00 -
From the Market
52 Week Low / High (₹) - / -
All Time Low / High (₹) - / -
Market Cap (₹ Cr.) 0
Equity (₹ Cr.) 0
Face Value (₹) -
Industry PE 43.4

Management X-Ray

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Valuation of Symbiotec Pharmalab - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales389.06418.52437.66409.61527.77531.19622.86633.85563.59673.61
Operating Expenses + 327.80346.25354.36318.97432.04411.80420.50528.55483.49530.67
Manufacturing Costs14.2024.0147.3337.0343.5145.2057.3755.5961.5769
Material Costs253.10249.25230.49202.32303.37257.03266.09354.23289.79321.57
Employee Cost 28.8042.0543.5849.3454.2564.4772.7781.7492.55101.60
Other Costs 31.7130.9432.9730.2930.9045.1124.2636.9939.5838.50
Operating Profit 61.2772.2783.3090.6495.73119.39202.37105.3080.09142.94
Operating Profit Margin (%) 15.7%17.3%19.0%22.1%18.1%22.5%32.5%16.6%14.2%21.2%
Other Income + 9.843.136.717.594.863.179.015.6512.3719.76
Exceptional Items 00000000-64.570
Interest 15.0224.0418.9517.5917.8310.616.523.078.057.54
Depreciation 10.8015.3718.5020.1620.1221.1622.1825.1127.6237.26
Profit Before Tax 45.2935.9952.5660.4862.6490.79182.6782.77-7.78117.90
Tax 14.928.753.8618.4916.5418.2747.1121.0414.8828.95
Profit After Tax 30.3727.2448.7041.9946.1072.52135.5661.73-22.6688.95
PAT Margin (%) 7.8%6.5%11.1%10.3%8.7%13.7%21.8%9.7%-4.0%13.2%
Adjusted EPS (₹)5.65.09.07.78.413.324.811.3-4.116.3
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund + 244.27271.51332.22374.25425.23497.83633.35695.18672.81761.14
Share Capital 10.8710.8710.8710.8710.9410.9410.9410.9410.9410.94
Reserves 233.40260.64321.35363.38414.29486.90622.42684.25661.88750.20
Debt +171.50182.02153.84132.92144.26117.5046.4163.25106.6751.25
Long Term Debt47.0438.0830.1912.625.682.471.460.731.411.12
Short Term Debt124.46143.94123.64120.30138.58115.0344.9562.52105.2650.13
Minority Interest0000000000
Trade Payables70.6090.3580.1364.47124.83108.02109.8284.8886.61226.92
Others Liabilities 42.2953.6150.3355.8447.4946.2152.2851.1749.0347.88
Total Liabilities 528.65597.50616.51627.47741.80769.55841.87894.48915.121,087.19

Fixed Assets

Net Fixed Assets +186.23224.82239.40227.01222.89229.62247.58266.09265.65323.82
Gross Block217.28270.95257.82265.60281.60309.01348.53391.57418.23513.66
Accumulated Depreciation31.0546.1318.4238.5958.7179.40100.94125.49152.59189.84
CWIP 30.552.831.176.7312.9730.5026.7322.6273.9019.36
Investments 102.4299.68103.31105.56111.33110.39122.59130.1765.6042.25
Inventories87.37126.07128.25127.94216.10230.85225.26245.41241.72332.61
Trade Receivables75.2799.41110.31122.78127.67106.92118.68143.66112.31125.43
Cash Equivalents 10.609.133.365.828.3228.5441.146.322.836.27
Others Assets 36.2235.5630.7231.6342.5232.7559.8980.22153.11237.45
Total Assets 528.65597.50616.51627.47741.80769.55841.87894.48915.121,087.19

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity + 28.4919.1752.2748.3243.74109157.7023.5193.35147.46
PBT 45.2935.9952.5660.4862.6490.79182.6782.77-7.78117.90
Adjustment 23.8634.5229.8031.1436.0133.7229.1322.9791.1525.36
Changes in Working Capital -30.88-46.38-17.37-27.91-40.228.68-11.57-58.8925.839.29
Tax Paid -9.79-4.96-12.72-17.30-13.25-24.19-42.53-23.34-15.82-35.09
Cash Flow From Investing Activity + -88.39-37.49-7.62-15.61-26.97-69.91-78.99-33.94-132.50-80.80
Capex -84.98-29.30-35.18-16-23.70-48.42-41.51-41.58-71.75-40.12
Net Investments 0039.9426.7117.6030.222.840.44029.07
Others -3.40-8.19-12.38-26.32-20.87-51.72-40.327.20-60.76-69.76
Cash Flow From Financing Activity + 70.13-6.93-44.34-31.70-14.19-42.23-79.0414.8436.53-62.98
Net Proceeds from Shares 0000500000
Net Proceeds from Borrowing 00-6.24000016.1700
Interest Paid -12.67-20.85-17.80-15.66-16.98-9.55-5.67-1.22-7.04-6.99
Dividend Paid 0000000000
Others 82.8113.92-20.30-16.04-2.21-32.68-73.38-0.1143.57-55.99
Net Cash Flow 10.24-25.250.3212.58-3.14-0.334.41-2.623.67

Finance Ratio

PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)13.2610.5616.1311.8911.5315.7123.979.29-3.3112.41
ROCE (%)16.213.3614.6915.1114.5216.9429.1211.930.0415.75
Asset Turnover Ratio0.850.750.740.660.770.70.80.740.620.67
PAT to CFO Conversion(x)0.940.71.071.150.951.51.160.38N/A1.66
Working Capital Days
Receivable Days60.7075.1085.60103.9086.6080.6064.307482.9064.40
Inventory Days72.9091.70103.70114.10119153.60130132.80157.70155.60
Payable Days97.60117.90135130.40113.90165.30149.40100.30108177.90

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Symbiotec Pharmalab Ltd FAQs

The current trading price of Symbiotec Pharmalab on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Symbiotec Pharmalab stood at ₹0.00 Cr

The latest P/E ratio of Symbiotec Pharmalab as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Symbiotec Pharmalab as of 31-Dec-1969 is 0.00.

The 52-week high of Symbiotec Pharmalab is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Symbiotec Pharmalab is ₹528 ( Cr.) .

About Symbiotec Pharmalab Ltd

No data to display
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×